The State of Clinical Trials in Africa: 2026 Outlook

Clinical trials in Africa are entering their most consequential decade since the field's modern beginnings. The continent that has historically hosted around 2–3% of the world's registered clinical trials — while carrying ~15% of the global population and ~25% of the global disease burden — is now the fastest-growing region for new trial starts, with regulatory modernisation, sponsor interest and platform maturity all compounding at once.

This piece is a ground-level look at where that stands in 2026: how big the activity actually is, who's investing and why, which regulatory shifts are moving the needle, and where the real infrastructure gaps remain.

How big is clinical research in Africa in 2026?

The most-cited baseline is the WHO International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov, which together capture the majority of interventional and observational studies globally. Their combined data shows African trial registrations climbing from a historical annual baseline of roughly 300–500 studies per year in the late 2010s to well over 1,200 new studies per year across the continent since 2023.

Distribution is heavily concentrated:

South Africa's dominance reflects three things: a mature regulator (SAHPRA, and its predecessor the MCC, have decades of GCP experience), world-class academic hospital sites, and the highest concentration of CROs on the continent. Kenya and Uganda punch above their weight because of the long-standing HIV, TB and malaria research infrastructure funded through Gates, the Wellcome Trust, EDCTP and PEPFAR.

Which therapeutic areas are actually driving the growth?

The historical picture — that African clinical research is "mostly infectious disease" — is out of date. Since 2022 the mix has shifted substantially:

• Infectious disease (HIV, TB, malaria, and post-COVID capabilities) remains the largest single category, at roughly 35% of active African trials.
• Oncology is now around 20% and growing double-digit year-on-year — driven by regional cancer incidence rising as non-communicable-disease burden grows and by sponsors seeking African-specific evidence for global submissions.
• Cardiometabolic (diabetes, hypertension, cardiovascular) is around 15%, again reflecting the epidemiological transition.
• Maternal, neonatal and paediatric studies remain a specialty African researchers lead globally.
• Genetic and rare-disease research is a small but fast-growing slice, benefiting from African populations' underrepresented but scientifically valuable genetic diversity.

Regulatory momentum: SAHPRA, EAC and the African Medicines Agency

Three regulatory tracks matter in 2026.

The African Medicines Agency (AMA) was established under an African Union treaty and moved into its operational phase in 2024, headquartered in Kigali. Its remit is continental — coordinating and harmonising medicine regulation across all 55 AU member states. The AMA won't replace national regulators, but it should progressively enable single-application, mutual-recognition pathways for products seeking approval in multiple African markets. Full harmonisation is a decade-plus project; the initial focus is high-priority medicines and public-health-relevant products.

SAHPRA, the South African Health Products Regulatory Authority, has been the continent's regulatory bellwether. Its modernisation programme includes:

• The eRIMS portal — a centralised digital submission system for market authorisations, Section 21 / Compassionate Use Medicine applications, clinical trial applications (CTF1 and its variants), and licensing. Phase 1 of eRIMS is live across four pathway categories; Phase 2 is expanding across nine additional programme areas covering pharmacovigilance, inspections, and 30+ individual work streams. See our Open Source eRIMS for Africa project for context on where this is heading.
• Timeline improvements — CTF1 review timelines have compressed from historical averages of 180+ days toward SAHPRA's target windows for standard applications.
• Compassionate Use Medicine — the rebranding of Section 21 reflects the same statutory basis but a clearer patient-centric framing.

The East African Community (EAC) has its own joint-review mechanism for medicines going through multiple EAC national regulators. Alongside the AMA, this is the second harmonisation track sponsors need to know about.

Why global sponsors are investing more in African trials

Five reasons, in the order sponsors typically raise them:

1. Recruitment velocity. African sites frequently recruit target numbers two to three times faster than equivalent US or European sites, particularly in oncology and infectious disease. Patient populations are often less exposed to standard-of-care therapies, which for many trial designs means cleaner comparator data.

2. Cost efficiency. Per-patient costs in African sites can run 30–50% below matched US sites, including data management, monitoring and site fees. This is a smaller factor for well-funded Phase 3 programmes but decisive for smaller sponsors and academic consortia.

3. Regulatory clarity. SAHPRA-approved clinical trial data is routinely accepted by the FDA and EMA under ICH-GCP mutual recognition. There is no meaningful discount applied to African trial data in global regulatory submissions when the trial is properly conducted.

4. Population representativeness. Regulators (FDA especially, under the 2022 FDORA legislation) now expect sponsors to demonstrate that pivotal trial populations are representative of the eventual treated population. For products expected to be used globally, African-recruited cohorts materially improve generalisability claims.

5. Genetic and phenotypic diversity. For therapeutic areas where drug metabolism, disease presentation or genetic variants matter — oncology, pharmacogenomics, rare disease — African populations contribute variation that simply cannot be replicated in European-ancestry cohorts.

What's still blocking wider adoption

Honest picture: the barriers are real, and they are largely infrastructural rather than scientific.

• Regulatory fragmentation. Fifty-five countries. Fifty-plus regulators. Different timelines, different requirements, different documentation standards. The AMA will help; it is not there yet.
• Site capacity variability. The gap between a Johannesburg academic hospital and a rural clinic in eastern DRC is enormous. Multi-site trials must plan for that heterogeneity from the start, not discover it at monitoring visit three.
• Data infrastructure. Bandwidth is patchier than sponsors assume, and power is patchier still. Any trial platform used at African sites needs to work fully offline and sync when it can — a design constraint most global EDC systems handle poorly. This is a deliberate design principle of our Nukleus platform.
• Perception lag. Some sponsors still carry outdated views of African trial data quality. This is decreasingly true — Q&A on monitor findings across a well-run African site network is comparable to comparable European sites — but the perception gap persists in some organisations.

The infrastructure gap — and how technology is closing it

Where the story turns from macro-trends to what's actually being built. Five technology categories are closing the historical infrastructure gap:

Clinical Trial Management Systems (CTMS). The operational backbone — sites, investigators, documents, training, timelines. For African trials specifically, CTMS platforms need to handle multi-country protocol variants, regulatory documentation packs per country, and site-capacity tracking that assumes heterogeneity. Our Kronus platform is one of the CTMS solutions built specifically for this shape.

Electronic Data Capture (EDC) with real offline support. Not "works with intermittent connection" — actually offline-first, where the tablet or laptop is the source of truth and the server is a sync target. Every action a clinical officer takes writes locally first; sync happens in batches when the network is available. See Nukleus for a working example of this architecture.

Pharmacovigilance platforms that handle African-specific adverse-event reporting requirements alongside FDA MedWatch, EudraVigilance, and national schemes. Integrated medical coding (MedDRA, WHO-DD, ICD-10, SNOMED) inside the same tool the safety officer uses avoids the traditional double-handling. Our SafetyBase platform runs this pattern.

Decentralised trial (DCT) capabilities — patient-reported outcomes via SMS, USSD, or tablet apps; remote monitoring; direct data capture from wearables and diagnostics. For low-connectivity patient populations, USSD outperforms SMS which outperforms app, and the platform choice matters more than the trial protocol sometimes admits.

Continental discovery platforms — the layer that lets sponsors find, evaluate and select African trial sites without having to build a network from scratch. This is the space our CTC.Africa project occupies, backed by the Gates Foundation, EDCTP and Science for Africa Foundation.

What to watch in 2026 and beyond

Three shifts are worth tracking:

1. AMA momentum. Watch the AMA's rollout of harmonised technical guidelines for CTA submissions. The first countries to fully participate will see step-changes in cross-border trial feasibility.
2. Data localisation. Multiple African countries have or are introducing data-protection laws (South Africa's POPIA is the template; Nigeria's NDPR, Kenya's Data Protection Act, and forthcoming legislation elsewhere follow similar shapes). Trial platforms must handle in-country residency requirements or route data appropriately.
3. AI in trial design and monitoring. The most credible current applications are in site selection (matching protocols to sites likely to recruit) and risk-based monitoring signal detection (finding data quality issues faster than a human monitor can). The wilder claims — AI-generated protocols, fully-autonomous safety review — remain unrealised in 2026.

Frequently asked questions

How many clinical trials are running in Africa in 2026? Aggregate registry data (WHO ICTRP + ClinicalTrials.gov) puts active or recently-active trials with at least one African site at roughly 5,000–6,000, with over 1,200 new registrations per year.

Which African country conducts the most clinical trials? South Africa, by a considerable margin — hosting an estimated 35–40% of all African trial activity. Egypt, Kenya, Nigeria and Uganda make up most of the remainder.

What is SAHPRA? The South African Health Products Regulatory Authority — the country's medicines regulator, established in 2018 to replace the Medicines Control Council. SAHPRA is responsible for the licensing, registration and post-market surveillance of all medicines, medical devices and IVDs sold or used in South Africa, and for approving clinical trials conducted there.

How long does it take to get a clinical trial approved in South Africa? Statutory review timelines for a standard Clinical Trial Application Form (CTF1) are 90 working days for scientific review; total elapsed time from submission to approval historically ranged 6–12 months. SAHPRA's eRIMS modernisation programme aims to compress this substantially.

Is African clinical trial data accepted by the FDA and EMA? Yes. Under ICH-GCP mutual recognition, data from properly-conducted trials at ICH-GCP-compliant sites in Africa (including all SAHPRA-approved sites) is accepted by both the US Food and Drug Administration and the European Medicines Agency for regulatory submissions.

What is the African Medicines Agency (AMA)? The AMA is the continental medicines regulator established under an African Union treaty, headquartered in Kigali, Rwanda. Its purpose is to coordinate and harmonise medicine regulation across AU member states — not to replace national regulators, but to enable mutual recognition pathways for cross-border approvals.

What software do African clinical trials typically use? Historically, trials in Africa used the same global EDC systems (Medidata, Veeva, Oracle) as trials anywhere. That is changing: Africa-built platforms including nuvoteQ's own Kronus (CTMS), Nukleus (EDC) and SafetyBase (PV) are now deployed across 65+ countries, designed from day one for the connectivity, regulatory-diversity and language constraints African trials actually face.

---

Want the next post in this series delivered when it lands? Subscribe below — new posts land every two to three weeks.